Active substance
Cefazolin
- SFDA 16
- US FDA 43
- Health Canada 15
- US price lines 1
- WHO EML 1
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TAZOLINE 0.5GM VIAL IV+10MLWATER FOR INJ | 500 mg | powder for solution for injection · Intravenous use | 1 Vial | SAR 9.65 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TAZOLINE 1GM VIAL I.M+5MLSOLV.LIDOCAINE | 1 g | powder for solution for injection · Intramuscular use | 1 Vial | SAR 19.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TAZOLINE 1GM VIAL IV+10ML WATER FOR INJ. | 1 g | powder for solution for injection · Intravenous use | 1 Vial | SAR 19.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TAZOLINE0.5GM VIAL I.M+5MLSOLV.LIDOCAINE | 0.5 g | powder for solution for injection · Intramuscular use | 1 Vial | SAR 9.65 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| ZEPILEN 1GM POWDER FOR SOLUTION FOR INJECTION/INFUSION | 1 g | powder for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 100.80 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| ZOLECIN | 1000 mg | Powder for injection · Intravenous use | 10 Vial | SAR 80.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZOLECIN 1GM VIAL I.V | 1 g | Powder for injection · Intravenous use | 1 Vial | SAR 19.25 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| CEFAZOLIN 0.5GM VIAL | 0.5 g | Solution · Parenteral use | 1 Vial | SAR 6.40 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| CEFAZOLIN 1GM VIAL | 1 g | Solution · Parenteral use | 1 Vial | SAR 11.20 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| KEFZOL 1 GM.-10 ML. VIAL | 1 g | Powder for injection · Intravenous use | 1 Vial | SAR 21.45 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| KEFZOL 250MG.-10ML. VIAL | 250 mg | Powder for injection · Intravenous use | 1 Vial | SAR 7.70 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| KEFZOL 500MG.-10 ML. VIAL | 500 mg | Powder for injection · Intravenous use | 1 Vial | SAR 14.10 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| ZOLECIN 250MG INJ IM-IV | 250 mg | Powder for injection · Intravenous use | 1 Vial | SAR 3.15 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| ZOLECIN 250MG INJ IM-IV | 250 mg | Powder for injection · Intravenous use | 1 Vial | SAR 3.40 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| ZOLECIN 500MG INJ IM-IV | 500 mg | Powder for injection · Intravenous use | 1 Vial | SAR 5.15 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| ZOLECIN 500MG INJ IM-IV | 500 mg | Powder for injection · Intravenous use | 1 Vial | SAR 5.75 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PYELONEPHRITIS; ANTIBIOTIC SURGICAL PROPHYLAXIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - IMPETIGO AND ECTHYMA; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - PURULENT SKIN AND SOFT TISSUE INFECTIONS (CUTANEOUS ABSCESSES, FURUNCLES, CARBUNCLES); BACTERIAL SKIN INFECTIONS - SURGICAL SITE INFECTIONS; DENTAL ABSCESS; ENDOCARDITIS; HIP AND KNEE REPLACEMENT SURGERY; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; INTRA-ABDOMINAL INFECTIONS; MATERNAL AND CHILD HEALTHCARE- PERINATAL,INTRAPARTUM AND POSTPARTUM CARE; OSTEOMYELITIS; PERITONITIS; PREVENTION AND CHEMOPROPHYLAXIS OF BACTERIAL MENINGITIS- MENINGOCOCCAL INFECTIONS PREVENTION (CHEMOPROPHYLAXIS); Pyogenic Arthritis; RENAL TRANSPLANT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CEFAZOLIN SODIUM | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | SANDOZ | Prescription | 9 Dec 1988 |
| CEFAZOLIN AND DEXTROSE | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 3GM BASE/VIAL | injectable · injection | B BRAUN | Prescription | 27 Jul 2000 |
| CEFAZOLIN SODIUM | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | HIKMA FARMACEUTICA | Prescription | 18 Sep 2001 |
| CEFAZOLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | HIKMA FARMACEUTICA | Prescription | 18 Oct 2004 |
| CEFAZOLIN SODIUM | EQ 100GM BASE/VIAL; EQ 300GM BASE/VIAL | injectable · injection | SAMSON MEDCL | Prescription | 29 Nov 2006 |
| CEFAZOLIN SODIUM | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | ACS DOBFAR | Prescription | 22 Oct 2008 |
| CEFAZOLIN SODIUM | EQ 10GM BASE/VIAL; EQ 20GM BASE/VIAL | injectable · injection | ACS DOBFAR | Prescription | 22 Oct 2008 |
| CEFAZOLIN IN DEXTROSE | EQ 2GM BASE/100ML (EQ 20MG BASE/ML); EQ 1GM BASE/50ML (EQ 20MG BASE/ML); EQ 3GM BASE/150ML (EQ 20MG BASE/ML) | solution · intravenous | BAXTER HLTHCARE CORP | Prescription | 7 Aug 2015 |
| CEFAZOLIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 3GM BASE/VIAL | injectable · injection | QILU ANTIBIOTICS | Prescription | 28 Dec 2015 |
| CEFAZOLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | QILU ANTIBIOTICS | Prescription | 17 Oct 2018 |
| CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL; EQ 3GM BASE/VIAL | powder · intravenous | HIKMA PHARMS | Prescription | 7 Oct 2022 |
| CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL; EQ 3GM BASE/VIAL | powder · intravenous | HQ SPCLT PHARMA | Prescription | 8 May 2023 |
| ANCEF | EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | GLAXOSMITHKLINE | Discontinued | 4 Oct 1973 |
| KEFZOL | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 10GM BASE/VIAL; EQ 20GM BASE/VIAL | injectable · injection | ACS DOBFAR | Discontinued | 2 Nov 1973 |
| KEFZOL | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | LILLY | Discontinued | 10 Sep 1985 |
| CEFAZOLIN SODIUM | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL; EQ 20GM BASE/VIAL | injectable · injection | HIKMA PHARMS | Discontinued | 12 Jan 1988 |
| CEFAZOLIN SODIUM | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | TEVA PHARMS | Discontinued | 14 Mar 1989 |
| CEFAZOLIN SODIUM | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | DR REDDYS | Discontinued | 29 Dec 1989 |
| CEFAZOLIN SODIUM | EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL; EQ 20GM BASE/VIAL | injectable · injection | DR REDDYS | Discontinued | 29 Dec 1989 |
| ANCEF IN PLASTIC CONTAINER | EQ 10MG BASE/ML; EQ 20MG BASE/ML | injectable · injection | BAXTER HLTHCARE | Discontinued | 28 Mar 1991 |
| CEFAZOLIN SODIUM | EQ 1GM BASE/VIAL | injectable · injection | FACTA FARMA | Discontinued | 27 Dec 1991 |
| CEFAZOLIN SODIUM | EQ 1GM BASE/VIAL | injectable · injection | STERI PHARMA | Discontinued | 27 Dec 1991 |
| CEFAZOLIN SODIUM | EQ 10GM BASE/VIAL; EQ 20GM BASE/VIAL | injectable · injection | FACTA FARMA | Discontinued | 27 Dec 1991 |
| CEFAZOLIN SODIUM | EQ 500MG BASE/VIAL | injectable · injection | FACTA FARMA | Discontinued | 27 Dec 1991 |
| CEFAZOLIN SODIUM | EQ 500MG BASE/VIAL | injectable · injection | STERI PHARMA | Discontinued | 27 Dec 1991 |
18 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CEFAZOLIN FOR INJECTION | 02108119 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | TEVA CANADA LIMITED |
| CEFAZOLIN FOR INJECTION | 02108127 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | TEVA CANADA LIMITED |
| CEFAZOLIN FOR INJECTION | 02437104 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | HIKMA CANADA LIMITED |
| CEFAZOLIN FOR INJECTION | 02437112 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | HIKMA CANADA LIMITED |
| CEFAZOLIN FOR INJECTION | 02437120 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | HIKMA CANADA LIMITED |
| CEFAZOLIN FOR INJECTION USP | 02308932 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| CEFAZOLIN FOR INJECTION USP | 02308959 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| CEFAZOLIN FOR INJECTION USP | 02308967 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| CEFAZOLIN FOR INJECTION, USP | 02237138 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFAZOLIN FOR INJECTION, USP | 02237140 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFAZOLIN FOR INJECTION, USP | 02401029 | 100 G / BAG | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFAZOLIN IN DEXTROSE INJECTION, USP | 02496313 | 20 MG / ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| CEFAZOLIN SODIUM FOR INJECTION BP | 02465469 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | STERIMAX INC |
| CEFAZOLIN SODIUM FOR INJECTION BP | 02465477 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| CEFAZOLIN SODIUM FOR INJECTION BP | 02524791 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | STERIMAX INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CEFAZOLIN 1 GM VIAL | $1.07031 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Other specified prophylactic measures; First choice: Other specified prophylactic measures (co-prescribed with metronidazole); Second choice: Bacterial infection of joint; Second choice: Osteomyelitis or osteitis
Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
Safety signals and safety-related labeling changes
- US FDA 31 Aug 2026 CEFAZOLIN IN DEXTROSE — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 13 Feb 2026 CEFAZOLIN SODIUM — safety-related labeling change
Labeling sections changed: Use in Specific Populations - EMA PRAC 15 Jan 2026 PRAC signal: Kounis syndrome
Action for MAH: update of the product information: Yes - EMA PRAC 4 Sep 2025 PRAC signal: Kounis syndrome
Action for MAH: update of the product information: No - US FDA 18 Dec 2024 CEFAZOLIN SODIUM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 26 Aug 2024 CEFAZOLIN AND DEXTROSE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 May 2024 CEFAZOLIN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.